After earning a degree in industrial and labor relations from Cornell University and a law degree from DePaul University’s College of Law, Anna Richo went on to a career in litigation, business ethics, and compliance in the pharmaceutical and biotechnology industry. Named one of FiercePharma’s Top 15 Women in Pharma, Anna Richo brings almost 30 years of experience to her role as executive vice president and general counsel for UCB S.A., a global biopharmaceutical company headquartered in Brussels, Belgium.
UCB works with patients and scientists to develop medicines for serious diseases, especially in the field of immunology and neurology. Parkinson’s disease, which is second only to Alzheimer’s disease as the most common neurodegenerative disorder, is a special focus of treatment.
Parkinson’s tends to come on late in life, usually after age 60, and slowly worsens with time, causing tremors and other symptoms. It is difficult to detect and diagnose early, and there is currently no cure. At present, around 6.3 million people all over the world have received a Parkinson’s diagnosis.
Parkinson’s is caused by a malfunction of dopamine production in the brain. Among other things, dopamine affects bodily movements, and in addition to tremors, Parkinson’s patients may have trouble sleeping and experience depression, anxiety, and dementia.
UCB manufactures a medicine called Neupro which doctors may prescribe with or without levodopa, a medicine that works to replace the brain’s lacking dopamine. This recommendation will depend on the stage of disease advancement and the prescription guidelines in Europe or the US. These drugs can greatly ease Parkinson’s symptoms, and some patients may also find complementary therapies like physiotherapy or reflexology helpful.
A proficient attorney with nearly three decades of experience, Anna Richo is a graduate of Cornell University and DePaul University where she obtained a Juris Doctor. In addition to her current work as the executive vice president and general counsel at UCB, an international biopharmaceutical firm in Belgium, Anna Richo has experience in law and executive management at Baxter International and Amgen. In her current work, Ms. Richo manages all legal matters, and has resolved approximately 4,600 cases of tort product liability litigation.
Tort law is generally defined as the sector of law that encompasses all civil lawsuits except for contractual disagreements, and holds the goal of addressing wrong done to an individual. Injuries are generally addressed through monetary compensation, otherwise known as damages. This area of law includes the three tort law categories of strict liability, negligent torts, and intentional torts.
– Strict liability law deals with an act rather than a person that actually commits harm, such as the production of a defective product.
– Negligent tort law deals with harm that stems from a person’s failure to exercise a reasonable standard of care, such as an accident.
– Intentional tort law deals with purposeful misconduct such as assault.
Anna Richo serves as executive vice president and general counsel for UCB, a biopharmaceutical firm focused on developing treatments for individuals with neurological and immunological disorders. A resident of Brussels, Anna Richo also belongs to the Institut des Juristes d’Entreprise, which offers members a number of educational seminars, including Antitrust Issues in the Digital Economy.
Hosted in collaboration with Crowell & Moring, Antitrust Issues in the Digital Economy will provide in-house counsels with up-to-date information and review with them pertinent legal proceedings, such as the German Asics case and the sector inquiry by the European Commission into European Union e-commerce. Speakers at the seminar will include representatives from the European Commission and partners from Crowell & Moring.
The seminar, which will be preceded by a networking lunch, will be held in Brussels on September 22, 2016, and members may register at no cost by September 19, 2016. To learn more about the seminar, visit IBJ.be.
Joining UCB in November 2012 as executive vice president and general counsel, Anna Richo previously held senior executive positions at other pharmaceutical and health care companies. The corporation that Anna Richo represents is listed by Forbes magazine on it Global 2000 List of companies.
Biopharmaceutical company UCB SA focuses on the fields of immunology and central nervous system disorders. It engages in research and development as well as commercialization of new drugs and solutions to help people suffering from severe diseases of the central nervous system or the immune system.
Its main immunology product is Cimzia, which is used to treat Crohn’s disease, axial spondyloarthritis, ankylosing spondylitis, rheumatoid arthritis, and psoriatic arthritis. UCB’s main neurology products include Briviact, Vimpat, and Keppra, which are all used for the treatment of epilepsy, and Neupro, which is used to treat Parkinson’s disease and restless legs syndrome.
UCB reaches millions of patients around the world with its products and solutions. It has more than 7,500 employees globally and does business in around 40 countries. Listed on the Euronext, it generated revenues of €3.8 billion in 2015.
UCB was founded in 1928 and is based in Brussels, Belgium.
The executive vice president and general counsel for UCB, a biopharmaceutical company, Anna Richo is an experienced legal professional. Throughout her distinguished career, Anna Richo has given speeches at events hosted by many prestigious organizations, including the NAACP, the Young Lawyers Section of the Chicago Bar Association, and the California Healthcare Institute.
Giving a great speech at a large-scale event can seem intimidating, but the following three tips may help make the practice much easier.
1. Talk about what you know: Some speakers are preoccupied with making bold statements for the sake of impact, but the most impactful statements often come from talking to the audience about topics that you find personally relate to. Passion drives energy, and speeches that draw from personal experience can leave a much more lasting impression.
2. Look confident: The audience will be more likely to consider your points if you look self-assured. Maintain good posture and be sure to make eye contact with your audience.
3. Change up your speech patterns: Monotone speech is going to leave your audience feeling disengage. Practice your speech in advance, experimenting with different tones and deciding which words to emphasize. Additionally, don’t forget to practice slowing down the speed of your speech, as nervous orators tend to deliver speeches quickly.
While serving Amgen Inc. as a senior vice president and chief compliance officer, Anna Richo, JD, has 25 years’ experience in the pharmaceutical and biotechnology industry. Anna Richo was highlighted in an online article by the Minority Corporate Counsel Association for her achievements overseeing litigation for companies such as the Baxter Healthcare Corporation.
Founded in 1997, the Minority Corporate Counsel Association (MCCA) supports attorneys of minority backgrounds in corporate legal departments and law firms. The organization focuses on research and training to build awareness about its mission. In addition, it publishes Diversity & The Bar, a magazine distributed to Association members every two months.
Diversity & The Bar reaches more than 35,000 readers, most of whom are senior in-house legal advisors and attorneys. The readership is split nearly in half between genders. Among the topics discussed in 2015 were best practices for diversity professionals, the winners of the MCCA’s Rainmakers Award, and the recipients of the Lloyd M. Johnson Jr. Scholarship. In addition, the magazine published a feature article about rising stars in the corporate legal field.
Based in Brussels, Belgium, as executive vice president and general counsel of biopharmaceutical company UCB, Anna Richo has more than two decades of experience in the biotech and pharmaceutical industries. A recognized industry speaker, Anna Richo is a member of several professional organizations, including the Women Business Leaders (WBL) of the U.S. Healthcare Industry Foundation.
With over 3,000 members in senior executive positions, the WBL of the U.S. Healthcare Industry Foundation was established in 2001 to help its members connect and promote their role in the industry. Comprised of leaders from life sciences companies, insurance providers, hospitals, and a variety of other health-care companies, the foundation offers free and dues-paying membership options depending on how intended member involvement.
Throughout the year, the foundation hosts a number of regional events and webinars, some of which qualify for education credits for the American College of Healthcare Executives. Its largest event, the annual three-day WBL Summit, is designed to provide a place for about 150 members to network and learn about trends and challenges in the industry. Attendance to the Summit is limited to preserve a close-knit atmosphere that encourages networking without being overwhelming. With representatives from across the country, it also gives a complete picture of the industry for members, their customers, and their business partners. Summit speakers are selected based on their relevancy to attendees and are encouraged to focus on executive skill-building to help propel the industry forward.
The next summit is scheduled for March 16-18, 2016. Slated to take place on Amelia Island, Florida, the summit is themed Innovative Leadership and will cover such topics as What Makes a Great Leader? and Are You Driving Change or Is It Driving You?